STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCRX
  4. [Form 4] Pacira BioSciences, Inc. Insider Trading Activity

Pacira BioSciences (PCRX) SVP Lauren Riker discloses stock sale and tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Pacira BioSciences Senior Vice President of Finance Lauren Riker reported two stock transactions in early January 2026. On January 2, 2026, 159 shares of Pacira common stock were withheld by the company at $24.46 per share to cover tax obligations when a restricted stock unit award vested. On January 5, 2026, Riker sold 1,416 shares of common stock at a price of $24.24 per share under a pre‑established Rule 10b5‑1 trading plan. After these transactions, Riker directly owned 59,064.242 shares of Pacira common stock, which includes 1,075.242 shares acquired through the company’s employee stock purchase plan in December 2025.

Positive

  • None.

Negative

  • None.
Insider RIKER LAUREN
Role Senior Vice President, Finance
Sold 1,416 shs ($34K)
Type Security Shares Price Value
Sale Common Stock 1,416 $24.24 $34K
Tax Withholding Common Stock 159 $24.46 $4K
Holdings After Transaction: Common Stock — 59,064.242 shares (Direct)
Footnotes (1)
  1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Includes 1,075.242 shares of common stock acquired under the issuer's employee stock purchase plan in December 2025. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RIKER LAUREN
(Last) (First) (Middle)
C/O PACIRA BIOSCIENCES, INC.
2000 SIERRA POINT PARKWAY, SUITE 900
(Street)
BRISBANE CA 94005
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Senior Vice President, Finance
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/02/2026 F 159(1) D $24.46 60,480.242(2) D
Common Stock 01/05/2026 S 1,416(3) D $24.24 59,064.242 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.
2. Includes 1,075.242 shares of common stock acquired under the issuer's employee stock purchase plan in December 2025.
3. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Remarks:
/s/ Kristen Williams, Attorney-in-Fact 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in Pacira BioSciences (PCRX) involved in this Form 4?

The reporting person is Lauren Riker, who serves as Senior Vice President, Finance of Pacira BioSciences, Inc..

How many Pacira BioSciences (PCRX) shares did Lauren Riker sell?

On January 5, 2026, Lauren Riker sold 1,416 shares of Pacira BioSciences common stock at a price of $24.24 per share.

Were any Pacira BioSciences (PCRX) shares withheld for taxes in this filing?

Yes. On January 2, 2026, 159 shares of Pacira common stock were withheld by the issuer to satisfy tax withholding obligations upon vesting of a restricted stock unit award.

How many Pacira BioSciences (PCRX) shares does Lauren Riker own after these transactions?

Following the reported transactions, Lauren Riker directly beneficially owned 59,064.242 shares of Pacira BioSciences common stock.

Does the Pacira BioSciences (PCRX) Form 4 mention an employee stock purchase plan?

Yes. The filing notes that the reported holdings include 1,075.242 shares acquired under Pacira’s employee stock purchase plan in December 2025.

Was the Pacira BioSciences (PCRX) stock sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the January 5, 2026 sale was made pursuant to a Rule 10b5‑1 trading plan previously adopted by Lauren Riker.